Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jenny C. Yang
Observed names:
J. Yang,
Jenny C Yang,
Jenny Yang
Institution:
Gilead Sciences (United States)
Observed institutions:
Chinese University of Hong Kong,
Texas Liver Institute,
Gilead Sciences (United States),
Gilead Sciences (France),
University at Buffalo, State University of New York
ORCID:
0000-0002-1625-3155
Observed ORCID:
0000-0002-1625-3155
OpenAlex ID:
A5102713731
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
2014
·
Nezam Afdhal
, Stefan Zeuzem
, et al.
·
New England Journal of Medicine
·
1,845
PDF
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
2014
·
Nezam Afdhal
, K. Rajender Reddy
, et al.
·
New England Journal of Medicine
·
1,388
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
2010
·
Lauren M. Lim
, Neang Ly
, et al.
·
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
·
512
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
2015
·
Susanna Naggie
, Curtis Cooper
, et al.
·
New England Journal of Medicine
·
498
PDF
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
2015
·
K. Rajender Reddy
, Marc Bourlière
, et al.
·
Hepatology
·
271
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
2022
·
Anna Kramvis
, Kyong-Mi Chang
, et al.
·
Nature Reviews Gastroenterology & Hepatology
·
227
PDF
Attenuation of Colistin Bactericidal Activity by High Inoculum ofPseudomonas aeruginosaCharacterized by a New Mechanism-Based Population Pharmacodynamic Model
2010
·
Jürgen B. Bulitta
, Jenny C. Yang
, et al.
·
Antimicrobial Agents and Chemotherapy
·
152
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV
2017
·
Chun-Jen Liu
, Wan-Long Chuang
, et al.
·
Gastroenterology
·
130
Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa
2008
·
Jürgen B. Bulitta
, Neang S. Ly
, et al.
·
Antimicrobial Agents and Chemotherapy
·
98
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
2015
·
Saleh A. Alqahtani
, Nezam Afdhal
, et al.
·
Hepatology
·
97
PDF
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
2015
·
David Wyles
, Paul Pockros
, et al.
·
Hepatology
·
90
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression
2022
·
Edward J. Gane
, P. Rod Dunbar
, et al.
·
Journal of Hepatology
·
86
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
2019
·
Anna S. Lok
, Fabien Zoulim
, et al.
·
Hepatology Communications
·
71
PDF
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection
2016
·
Mark S. Sulkowski
, Wan-Long Chuang
, et al.
·
Clinical Infectious Diseases
·
71
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
2016
·
Edward J. Gane
, Kris V. Kowdley
, et al.
·
Gastroenterology
·
61
PDF
Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
2015
·
Julius M. Wilder
, Lennox J. Jeffers
, et al.
·
Hepatology
·
60
PDF
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
2016
·
Eric Lawitz
, Nancy Reau
, et al.
·
Gastroenterology
·
55
The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
2017
·
Edward J. Gane
, Sophie Metivier
, et al.
·
Hepatology Communications
·
43
Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa
2012
·
Neang S. Ly
, Jenny Yang
, et al.
·
Antimicrobial Agents and Chemotherapy
·
40
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers
2012
·
Lillian S. L. Ting
, Jens Praestgaard
, et al.
·
Antimicrobial Agents and Chemotherapy
·
35
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
2016
·
Jia‐Horng Kao
, Rong‐Nan Chien
, et al.
·
Liver International
·
29
PDF
Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
2016
·
Wan‐Long Chuang
, Rong‐Nan Chien
, et al.
·
Journal of Gastroenterology and Hepatology
·
28
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
2023
·
Harry L. Janssen
, Young-Suk Lim
, et al.
·
JHEP Reports
·
27
PDF
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
2018
·
Lai Wei
, Masao Omata
, et al.
·
Antiviral Research
·
26
Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor
2017
·
Eric Lawitz
, Jenny C Yang
, et al.
·
Antiviral Therapy
·
26
Show more works
View as search
Works count:
48
Citation count:
6,099
H-index:
25
I10-index:
31
Year
Topic
Type